Urgent

Myeloma cast nephropathy

Renal · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

AKI in multiple myeloma from free light chains precipitating with Tamm-Horsfall protein forming obstructive tubular casts; often precipitated by dehydration, hypercalcaemia or nephrotoxins.

Figures & algorithms

Rouleaux
Rouleaux

Red flags

  • Severe AKI/oliguria
  • Severe hypercalcaemia
  • Hyperkalaemia/acidosis needing dialysis
  • Cord compression/other myeloma emergencies

Assessment

Differential diagnosis

  • Pre-renal AKI
  • Hypercalcaemic nephropathy
  • Contrast nephropathy
  • Light-chain deposition disease
  • Amyloidosis

Investigations

  • U&E, calcium, FBC, film
  • Serum free light chains and protein electrophoresis, urine Bence-Jones protein
  • Serum/urine immunofixation
  • Renal ultrasound; renal biopsy in selected cases

Management

  • Aggressive IV hydration to increase light-chain clearance
  • Treat hypercalcaemia
  • Stop nephrotoxins (NSAIDs, avoid contrast where possible)
  • Urgent haematology referral to start anti-myeloma therapy (e.g. bortezomib-based)
  • Consider extracorporeal light-chain removal in selected cases
  • Supportive dialysis if needed

Drugs & doses

IV crystalloid (aggressive hydration)
Treat hypercalcaemia (fluids, bisphosphonate)
Anti-myeloma chemotherapy (haematology-led)
Avoid nephrotoxins

Disposition

Admit; haematology and nephrology co-management.

Complications & pitfalls

  • Dialysis-dependent renal failure
  • Recurrent AKI
  • Complications of myeloma

Exam pearls

  • Rapid reduction of light chains offers the best chance of renal recovery
  • Avoid contrast and NSAIDs
  • Suspect myeloma in unexplained AKI with anaemia, hypercalcaemia or bone pain

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.